29.02.2024 22:30:05 - dpa-AFX: GNW-Adhoc: Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
Nyxoah to Participate in the Oppenheimer 34(th) Annual Healthcare MedTech &
Services Conference
Mont-Saint-Guibert, Belgium - February 29, 2024, 10:30pm CET / 4:30pm ET -
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a
medical technology company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced
that the Company will participate in the Oppenheimer 34(th) Annual Healthcare
MedTech & Services Conference, which takes place March 12 - 13, 2024.
Olivier Taelman, Nyxoah's Chief Executive Officer, will deliver a corporate
presentation on Tuesday, March 12, 2024, at 10:40am ET. A webcast
(https://wsw.com/webcast/oppenheimer34/nyxh.br/3385819) of the presentation will
be available in the Events section of Nyxoah's Investor Relations website. The
Company will be available for 1x1 meetings with institutional investors.
Nyxoah's Investor Presentation can be accessed on the Shareholder Information
(https://investors.nyxoah.com/shareholder-information) section of the Company's
Investor Relations page.
About Nyxoah
Nyxoah is a medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive Sleep Apnea
(OSA). Nyxoah's lead solution is the Genio® system, a patient-centered, leadless
and battery-free hypoglossal neurostimulation therapy for OSA, the world's most
common sleep disordered breathing condition that is associated with increased
mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision
that OSA patients should enjoy restful nights and feel enabled to live their
life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system
received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on
Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the
positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval
for the expansion of its therapeutic indications to Complete Concentric Collapse
(CCC) patients, currently contraindicated in competitors' therapy. Additionally,
the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S.
commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution - CE marked since 2019. Investigational device in the United States.
Limited by U.S. federal law to investigational use in the United States.
Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com (mailto:David.demartino@nyxoah.com)
+1 310 310 1313
Â